Phio Receives Nasdaq Bid-Price Deficiency Notice, Has 180 Days to Regain $1.00 Compliance
PHIO is trading near its 52-week low of $0.64 (2.6% above the low).
Summary
Phio has 180 days, until May 17, 2027, to lift its share price back above $1.00 after Nasdaq flagged 30 consecutive closes below the minimum. The listing stands for now, but the clock is running against a company already carrying going-concern doubt.
Key Events · Legal and Risk Events · PHIO
-
Nasdaq Bid-Price Deficiency Notice
Nasdaq notified Phio on November 16, 2026 that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days under Listing Rule 5550(a)(2).
-
180-Day Cure Period to May 17, 2027
Phio has until May 17, 2027 to regain compliance; a closing bid of at least $1.00 for 10 consecutive business days during that window would satisfy Nasdaq.
-
Listing Intact for Now
The notice has no immediate effect on the Nasdaq listing or trading of the common stock, and the company says it will monitor the bid price and evaluate options.
-
Going-Concern Backdrop
The notice follows the previously disclosed Q3 10-Q warning of substantial doubt about the company's ability to continue as a going concern with $10.6M of cash.
Analysis · PHIO · Life Sciences
The listing is not immediately at risk, but Phio now has until May 17, 2027 to lift its bid back to $1.00 for 10 consecutive business days after Nasdaq notified the company on November 16, 2026 that its stock had closed below $1.00 for 30 straight business days. The stakes are real: this arrives alongside previously disclosed going-concern doubt and only $10.6M of cash. A reverse split is the usual fix, and that would come on top of an already battered share price near its 52-week low. A second deficiency or a failed cure puts delisting on the table.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHIO was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8M. The 52-week trading range was $0.64 to $1.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.